Revolution Medicines to Participate in March 2025 Investor Conferences

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.

The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:

• TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
• 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET

Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences.

Details of the company’s participation are as follows:

• TD Cowen 45^th Annual Healthcare Conference
  • Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET

• Barclays 27^th Annual Global Healthcare Conference
  • Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET

• 2025 Leerink Partners Global Healthcare Conference
  • Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET

To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When is Revolution Medicines (RVMD) presenting at the TD Cowen Healthcare Conference in March 2025?

Revolution Medicines will present at the TD Cowen Healthcare Conference on Monday, March 3, 2025, at 1:50 p.m. ET.

What investor conferences is RVMD attending in March 2025?

RVMD is participating in three conferences: TD Cowen Annual Healthcare Conference, Barclays Global Healthcare Conference, and Leerink Partners Global Healthcare Conference.

How long will RVMD's conference webcasts be available for replay?

The webcasts will be available for replay on the company's website for at least 14 days following the live events.

What type of cancer treatments is Revolution Medicines (RVMD) developing?

Revolution Medicines is developing novel targeted therapies specifically for patients with RAS-addicted cancers.

Where can investors access RVMD's March 2025 conference webcasts?

Investors can access the live and archived webcasts through Revolution Medicines' investor relations website at https://ir.revmed.com/events-and-presentations.